OncoMatch/Pancreatic Cancer (PDAC)/BRCA2
Pancreatic Cancer (PDAC)BRCA2 Clinical Trials
Germline BRCA2 pathogenic variants are the most common hereditary cause of pancreatic cancer (~3–5% of PDAC) and predict sensitivity to platinum-based chemotherapy and PARP inhibition. Olaparib maintenance is FDA-approved for germline BRCA1/2-positive metastatic PDAC with response to first-line platinum. Active trials study PARP inhibitor combinations, somatic BRCA2 eligibility expansion, and neoadjuvant BRCA-targeted strategies.
Top recruiting BRCA2 Pancreatic Cancer (PDAC) trials
Ranked by phase and US site count.
See all trials matched to your profile →The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins University
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
AstraZeneca
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Exelixis
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
Dana-Farber Cancer Institute
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Therapy in Cancers With Mutations in DNA Repair Genes
University of California, San Francisco